JP2009541319A5 - - Google Patents

Download PDF

Info

Publication number
JP2009541319A5
JP2009541319A5 JP2009516542A JP2009516542A JP2009541319A5 JP 2009541319 A5 JP2009541319 A5 JP 2009541319A5 JP 2009516542 A JP2009516542 A JP 2009516542A JP 2009516542 A JP2009516542 A JP 2009516542A JP 2009541319 A5 JP2009541319 A5 JP 2009541319A5
Authority
JP
Japan
Prior art keywords
composition
biological substance
agent
biological
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009516542A
Other languages
English (en)
Japanese (ja)
Other versions
JP5319523B2 (ja
JP2009541319A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/014274 external-priority patent/WO2007149433A2/en
Publication of JP2009541319A publication Critical patent/JP2009541319A/ja
Publication of JP2009541319A5 publication Critical patent/JP2009541319A5/ja
Application granted granted Critical
Publication of JP5319523B2 publication Critical patent/JP5319523B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009516542A 2006-06-19 2007-06-19 リポソマーゼによる治療物質の腫瘍特異的送達 Active JP5319523B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81454606P 2006-06-19 2006-06-19
US60/814,546 2006-06-19
PCT/US2007/014274 WO2007149433A2 (en) 2006-06-19 2007-06-19 Tumor-specific delivery of therapeutic agents via liposomase

Publications (3)

Publication Number Publication Date
JP2009541319A JP2009541319A (ja) 2009-11-26
JP2009541319A5 true JP2009541319A5 (enExample) 2010-08-05
JP5319523B2 JP5319523B2 (ja) 2013-10-16

Family

ID=38834068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009516542A Active JP5319523B2 (ja) 2006-06-19 2007-06-19 リポソマーゼによる治療物質の腫瘍特異的送達

Country Status (5)

Country Link
US (4) US8444963B2 (enExample)
JP (1) JP5319523B2 (enExample)
KR (1) KR101376634B1 (enExample)
CN (1) CN101489593B (enExample)
WO (1) WO2007149433A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210589B1 (en) * 2009-01-22 2015-05-06 Ludwig-Maximilians-Universität München Vesicular phospholipid gels comprising proteinaceous substances
WO2012054717A2 (en) * 2010-10-21 2012-04-26 The Johns Hopkins University Detecting and treating solid tumors through selective disruption of tumor vasculature
EP2873726B1 (en) 2012-07-13 2018-09-05 Teikyo Heisei University Antitumor agent, marker for tumor detection, and oral vaccine agent
EP3265063A4 (en) 2015-03-03 2018-11-07 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
CN108136031B (zh) * 2015-10-07 2022-02-18 盐水港精糖株式会社 包含紫杉烷化合物的脂质体
US20240254434A1 (en) 2019-12-18 2024-08-01 Exomnis Biotech Bv Genetically modified clostridium strains and uses thereof
WO2023182420A1 (ja) * 2022-03-23 2023-09-28 国立研究開発法人理化学研究所 悪性腫瘍を治療するための組み合わせ医薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FI20031528A0 (fi) * 2003-10-17 2003-10-17 Ctt Cancer Targeting Tech Oy Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi
JP2005298486A (ja) * 2004-03-15 2005-10-27 Nipro Corp リポソームを含む癌治療用医薬組成物
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US20090117176A1 (en) * 2004-10-26 2009-05-07 Pharma Mar, S.A. Sociedad Unipersonal Anticancer Treatments

Similar Documents

Publication Publication Date Title
JP2009541319A5 (enExample)
Liang et al. The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat
KR100386492B1 (ko) 괴사유발물질과괴사에의해활성화되는물질을함유하는,종양및염증질환치료용배합제제로서의약제학적조성물
Makky et al. Biomimetic liposomes and planar supported bilayers for the assessment of glycodendrimeric porphyrins interaction with an immobilized lectin
US12178885B2 (en) Method for mediating targeted delivery of a composition to the brain of a subject in need thereof
JP2023022242A (ja) がんを処置するための方法および組成物
Zhang et al. Enhancing antitumor efficacy of nucleoside analog 5-fluorodeoxyuridine on HER2-overexpressing breast cancer by affibody-engineered DNA nanoparticle
CA3088122A1 (en) Altering inflammatory states of immune cells in vivo by modulating cellular activation states
KR101376634B1 (ko) 리포좀아제에 의한 치료제의 종양­특이적 전달
KR20190013929A (ko) 약물-전달 나노입자 및 약물 내성암에 대한 치료
US20210162030A1 (en) Compositions and methods for treatment of cancer with lekti
CN113144172B (zh) 一种含有万古霉素、ir780与携氧全氟己烷的脂质体的制备方法
Barzelighi et al. Investigating the effect of rAzurin loaded mesoporous silica nanoparticles enwrapped with chitosan-folic acid on breast tumor regression in BALB/C mice
Muñoz Madero et al. Electrochemotherapy for treatment of skin and soft tissue tumours. Update and definition of its role in multimodal therapy
WO2005061531A1 (en) A superantigen fusion protein used for antitumor therapy and the preparation thereof
Bachran et al. Chimeric toxins inhibit growth of primary oral squamous cell carcinoma cells
Mross et al. DNA-intercalators—the anthracyclines
Leighl et al. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer
JP2022545429A (ja) がん治療のための化学療法剤とα－ラクトグロブリン－オレイン酸複合体との組合せ
Ando et al. Targeted delivery of interferon gamma using a recombinant fusion protein of a fibrin clot–binding peptide with interferon gamma for cancer gene therapy
US9371523B2 (en) Cell migration regulator
Cortes-Funes et al. 5017 Multinational study (n= 2041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): updated results of MO19391
AU2024211936A1 (en) Compositions, systems, and methods for reducing adipose tissue
Fehr DNA Aptamer-Drug Targeting Chemotherapy: Investigation of Cell Cycle Inhibition via S15 Aptamer–Norcantharidin Complex
CN118217416A (zh) 一种用于肿瘤治疗的载有凝血酶的四面体结构dna